Lowers serum urate through uricosuric activity by reducing renal tubular urate reabsorption; published pharmacology also describes non-purine xanthine oxidase inhibition. The relative contribution of each action depends on the source and product.
Indications / reported uses
Treatment of chronic hyperuricaemia and gout in selected patients where authorised, generally when first-line urate-lowering therapy is unsuitable or ineffective. It is not for treatment of an acute gout attack. Use is limited in many jurisdictions because of serious hepatotoxicity, including reports of fatal liver injury.
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
ERA assessment scope
Project-specific environmental risk assessment support
The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.
Phase I exposure screening and trigger evaluation.
Environmental fate and ecotoxicity review, with Phase II work where required.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope
Environmental Risk Assessment (ERA)
ReguSight provides project-specific support for the Benzbromarone Environmental Risk Assessment (ERA) (the Benzbromarone ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.
Assessment may cover
Product, active-substance identity, formulation, route and intended-market review.
Phase I environmental exposure screening and applicable trigger evaluation.
Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
Data-gap analysis, study strategy, assumptions and scientific reporting.
The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.